178.81
Overview
News
Price History
Option Chain
Financials
Why MASI Down?
Discussions
Forecast
Dividend History
Masimo Corp stock is traded at $178.81, with a volume of 673.05K.
It is up +0.10% in the last 24 hours and up +0.16% over the past month.
Masimo Corp is a medical technology company. The company oepates in single segment namely Healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. The company sells its products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, and others.
See More
Previous Close:
$178.64
Open:
$178.68
24h Volume:
673.05K
Relative Volume:
0.50
Market Cap:
$9.36B
Revenue:
$1.56B
Net Income/Loss:
$216.80M
P/E Ratio:
122.64
EPS:
1.458
Net Cash Flow:
$206.10M
1W Performance:
+0.19%
1M Performance:
+0.16%
6M Performance:
+19.81%
1Y Performance:
+19.28%
Masimo Corp Stock (MASI) Company Profile
Name
Masimo Corp
Sector
Industry
Phone
949-297-7000
Address
52 DISCOVERY, IRVINE, CA
Compare MASI vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
MASI
Masimo Corp
|
178.81 | 9.36B | 1.56B | 216.80M | 206.10M | 1.458 |
|
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Masimo Corp Stock (MASI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-17-25 | Initiated | BofA Securities | Neutral |
| Dec-27-24 | Reiterated | Raymond James | Outperform |
| Nov-06-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-15-24 | Upgrade | Stifel | Hold → Buy |
| Mar-25-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-24 | Downgrade | Jefferies | Buy → Hold |
| Jan-03-24 | Downgrade | Needham | Buy → Hold |
| Nov-08-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-18-23 | Downgrade | Stifel | Buy → Hold |
| Jul-10-23 | Initiated | Wells Fargo | Equal Weight |
| Feb-22-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-15-22 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-05-22 | Reiterated | Needham | Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Sep-15-22 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-14-22 | Initiated | Loop Capital | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Peer Perform |
| Feb-18-22 | Upgrade | Needham | Hold → Buy |
| Feb-16-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-12-21 | Resumed | Raymond James | Mkt Perform |
| Sep-02-20 | Initiated | Robert W. Baird | Outperform |
| Aug-14-20 | Resumed | Piper Sandler | Overweight |
| Apr-20-20 | Downgrade | Needham | Buy → Hold |
| Mar-02-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-07-19 | Reiterated | Needham | Buy |
| Apr-16-19 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-13-19 | Reiterated | Needham | Buy |
| Dec-19-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-14-18 | Initiated | Needham | Buy |
| Mar-09-18 | Initiated | Barclays | Overweight |
| Aug-14-17 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-04-17 | Reiterated | Wedbush | Outperform |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-27-17 | Reiterated | Wedbush | Outperform |
| Feb-13-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-04-16 | Reiterated | Wedbush | Outperform |
| May-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-05-16 | Reiterated | Wedbush | Outperform |
| Jan-06-16 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-05-15 | Reiterated | ROTH Capital | Buy |
View All
Masimo Corp Stock (MASI) Latest News
Masimo Corp at JPMorgan Healthcare Conference Transcript - GuruFocus
Wearables in Pharma & Biotech Research and Forecasts Report 2026-2031, Company Profiles and Market Strategies of Abbott, Dexcom, and Masimo - Yahoo Finance
WATER ISLAND CAPITAL LLC's Masimo Corp(MASI) Holding History - GuruFocus
Masimo Corp stock (US5747951003): earnings, Danaher deal and what’s next for the medical-tech spec - AD HOC NEWS
Danaher Masimo Deal Shifts Growth Outlook And Investor Focus - Yahoo Finance
Pentwater discloses 3.18M-share stake in Masimo (MASI) - Stock Titan
[SCHEDULE 13G] MASIMO CORP Passive Investment Disclosure (>5%) - Stock Titan
Joe Kiani holds 3.66M shares of Masimo (NASDAQ: MASI), cites disputed awards - Stock Titan
MASI Stock Price, Quote & Chart | MASIMO CORP (NASDAQ:MASI) - ChartMill
All eyes on Masimo earnings amid pending Danaher takeover - Investing.com
Swedbank AB Sells 8,000 Shares of Masimo Corporation $MASI - MarketBeat
Comerica Bank Lowers Stock Holdings in Masimo Corporation $MASI - MarketBeat
Masimo Shareholder Notice - TMX Newsfile
Masimo Corporation (MASI) Rose Following the Acquisition Announcement - Yahoo Finance
Masimo Shareholder Action Reminder - TMX Newsfile
Wilson Asset Management International PTY Ltd. Increases Stock Position in Masimo Corporation $MASI - MarketBeat
Masimo Corporation Q1 2026 Financial Results: Revenue, Net Income, and Key Financial Highlights - Minichart
Masimo Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Masimo Corp (FRA:3M4) Stock Price & 30 Year Financial Data - GuruFocus
Masimo : Quarterly Report for Quarter Ending April 4, 2026 (Form 10-Q) - marketscreener.com
Masimo Corp. stockholders adopted Danaher merger agreement May 1 - MLex
Masimo Corp 1Q 2026: Revenue $403.6M, Net income $57.1M, EPS $1.09— 10-Q Summary - TradingView
Danaher to acquire Masimo (NASDAQ: MASI) in $180 per share cash deal - Stock Titan
Masimo Corporation Reports Earnings Results for the First Quarter Ended April 04, 2026 - marketscreener.com
Masimo (MASI) director gets new RSU grant and converts prior award - Stock Titan
Masimo (MASI) director awarded 1,119 RSUs and exercises 1,225 units - Stock Titan
Masimo (MASI) chair exercises 1,225 RSUs and receives 1,119-unit grant - Stock Titan
Masimo (MASI) CHRO nets RSU shares after tax-withholding share disposition - Stock Titan
Vanguard Group Inc. Sells 461,225 Shares of Masimo Corporation $MASI - MarketBeat
Masimo Shareholders Approve $180 Per Share Acquisition by Danaher, Merger Expected to Close in 2026 - Minichart
Masimo shareholders give green light to $10B acquisition by Danaher - MassDevice
Masimo Shareholders Approve $9.9B Sale to Danaher - Orange County Business Journal
Masimo shareholders approve its $9.9B acquisition by Danaher - Modern Healthcare News
Masimo Shareholders OK $9.9B Merger Deal with Danaher - Medical Product Outsourcing
Masimo shareholders approve $180 per share Danaher acquisition - Investing.com
Masimo Shareholders Approve Acquisition by Danaher - marketscreener.com
Masimo (NASDAQ: MASI) shareholders back $180 cash acquisition by Danaher - Stock Titan
Masimo nears Danaher sale after shareholder vote backs cash merger - Stock Titan
Masimo Corporation $MASI Shares Purchased by UBS Group AG - MarketBeat
Is Masimo Corporation (MASI) A Good Stock To Buy Now? - Yahoo Finance
Danaher deal finalized: Company to acquire Masimo for $9.9 billion in cash - MSN
MASI SEC FilingsMasimo Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Masimo (MASI) 10-K/A adds governance, CEO pay terms and Danaher merger plans - Stock Titan
Masimo SET Shows Accurate Pulse Oximetry in Newborns of All Skin Tones - Yahoo Finance
MSN Money - MSN
BlackRock (MASI) holds 116,871 shares of Masimo — 0.2% stake - Stock Titan
Masimo Corporation (NASDAQ:MASI) Short Interest Update - MarketBeat
M&T Bank Corp Purchases 6,578 Shares of Masimo Corporation $MASI - MarketBeat
Danaher Euro Debt Raise Reshapes Masimo Deal And Valuation Story - Yahoo Finance
€2.98B Danaher (NYSE: DHR) euro notes to support Masimo acquisition - Stock Titan
Danaher to buy medical tech firm Masimo for $9.9 billion - MSN
Masimo Corp Stock (MASI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):